These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 34241908)

  • 1. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
    Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
    Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.
    Ong MZ; Kimberly SA; Lee WH; Ling M; Lee M; Tan KW; Foo JB; Yow HY; Sellappans R; Hamzah S
    Curr Pharm Biotechnol; 2024; 25(11):1377-1393. PubMed ID: 39034731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Manufacturing Procedures on CAR T Cell Functionality.
    Watanabe N; Mo F; McKenna MK
    Front Immunol; 2022; 13():876339. PubMed ID: 35493513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
    Khvorost D; Kendall B; Jazirehi AR
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
    Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
    Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia.
    Alayoubi AM; Khawaji ZY; Mohammed MA; Mercier FE
    Ann Hematol; 2024 Jun; 103(6):1805-1817. PubMed ID: 37736806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
    Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
    Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
    Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
    Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
    Wei W; Chen ZN; Wang K
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor (CAR) T-Cell Therapy in Hematologic Malignancies: Clinical Implications and Limitations.
    Blüm P; Kayser S
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy to get on point with base editing.
    Harbottle JA
    Drug Discov Today; 2021 Oct; 26(10):2350-2357. PubMed ID: 33857616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology.
    Tao R; Han X; Bai X; Yu J; Ma Y; Chen W; Zhang D; Li Z
    Front Immunol; 2024; 15():1354825. PubMed ID: 38449862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
    Thavorn K; Thompson ER; Kumar S; Heiskanen A; Agarwal A; Atkins H; Shorr R; Hawrysh T; Chan KK; Presseau J; Ollendorf DA; Graham ID; Grimshaw JM; Lalu MM; Nochaiwong S; Fergusson DA; Hutton B; Coyle D; Kekre N
    Value Health; 2024 Aug; 27(8):1149-1173. PubMed ID: 38641057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.